HeartSciences (NASDAQ:HSCS) Price Target Lowered to $8.00 at Ascendiant Capital Markets

HeartSciences (NASDAQ:HSCS) had its price objective lowered by Ascendiant Capital Markets from $9.00 to $8.00 in a research note released on Tuesday,Benzinga reports. Ascendiant Capital Markets currently has a buy rating on the stock.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a report on Monday, December 29th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $8.00.

HeartSciences Stock Performance

Shares of NASDAQ:HSCS opened at $2.43 on Tuesday. The company’s 50 day simple moving average is $2.94 and its 200 day simple moving average is $3.02. The stock has a market capitalization of $7.73 million, a price-to-earnings ratio of -0.49 and a beta of 2.53. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.19 and a quick ratio of 1.04. HeartSciences has a 1 year low of $2.01 and a 1 year high of $6.47.

HeartSciences (NASDAQ:HSCS) last released its earnings results on Thursday, March 12th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.21. As a group, research analysts predict that HeartSciences will post -10.01 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Geode Capital Management LLC bought a new stake in shares of HeartSciences in the 2nd quarter valued at about $43,000. TFB Advisors LLC bought a new position in shares of HeartSciences during the third quarter worth about $105,000. Finally, DRW Securities LLC raised its position in shares of HeartSciences by 13.7% during the fourth quarter. DRW Securities LLC now owns 95,065 shares of the company’s stock worth $294,000 after acquiring an additional 11,455 shares during the last quarter. 17.24% of the stock is owned by institutional investors and hedge funds.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.